PCSK9 Functions in Atherosclerosis Are Not Limited to Plasmatic LDL-Cholesterol Regulation

Area of Science:

• Cardiovascular Biology
• Molecular Medicine
• Atherosclerosis Research

Background:

• Proprotein convertase subtilisin/kexin type 9 (PCSK9) is recognized for its role in regulating low-density lipoprotein cholesterol (LDL-C) levels.
• PCSK9 inhibition therapies have shown significant benefits in patients with atherosclerosis.
• Emerging evidence suggests PCSK9 influences multiple pathways in cardiovascular disease pathogenesis.

Purpose of the Study:

• To review the multifaceted roles of PCSK9 in atherosclerosis progression.
• To explore PCSK9's functions beyond its impact on plasma lipid levels.
• To evaluate recent findings on PCSK9's involvement in cardiovascular disease mechanisms.

Main Methods:

• Literature review of recent studies on PCSK9 function in atherosclerosis.
• Analysis of data linking PCSK9 to lipid metabolism, inflammation, and thrombosis.
• Evaluation of therapeutic strategies targeting PCSK9.

Main Results:

• PCSK9 regulates macrophage lipid uptake, foam cell formation, and atherosclerotic plaque development.
• PCSK9 influences vascular inflammation, cytokine release, and plaque destabilization.
• PCSK9 modulates platelet function, leukocyte recruitment, and clot formation, impacting thrombosis.
• Inhibition of PCSK9 activity demonstrably reduces atherosclerosis progression.

Conclusions:

• PCSK9 is a critical mediator in atherosclerosis, acting through mechanisms independent of LDL-C regulation.
• Targeting PCSK9 offers a promising therapeutic strategy for cardiovascular diseases by addressing multiple pathological pathways.
• Further research into PCSK9's diverse functions can lead to novel treatment approaches for atherosclerosis and related conditions.